Meeting Unmet Needs in HS With UCB’s Dr. Jeff Stark
Jeff Stark, MD, Vice President and Head of Immunology at UCB discusses the recent U.S. Food and Drug Administration approval of bimekizumab-bkzx (Bimzelx, UCB) for the treatment of moderate-to-severe hidradenitis suppurativa (HS) in adults and what it means to the HS community.